Meeting
2024 ASCO Genitourinary Cancers Symposium
Phase II study of pembrolizumab in combination with radiation with or without olaparib in localized high-risk prostate cancer.
Authors
Zin Myint
University of Kentucky, Lexington, KY
Zin Myint , William H St. Clair , Stephen Strup , Patrick J. Hensley , Donglin Yan , Jonathan David Tward , Benjamin L. Maughan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT 05568550
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr TPS351)
DOI
10.1200/JCO.2024.42.4_suppl.TPS351
Abstract #
TPS351
Poster Bd #
R3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Post radical prostatectomy (RP) PSA outcomes following 6 vs 18 months of perioperative androgen deprivation therapy (ADT) in men with localized high risk prostate cancer (LHRPC): Results of Part 2 of a randomized phase 2 trial.
First Author: Rana R. McKay
Poster
2023 ASCO Annual Meeting
Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial.
First Author: Ryan Phillips
Poster
2021 Genitourinary Cancers Symposium
Preoperative predictors of biochemical recurrence in a phase II trial of neoadjuvant therapy in very high-risk prostate cancer.
First Author: Ashanda Rosetta Patrice Esdaille
Poster
2019 Genitourinary Cancers Symposium
Early predicting factor for biochemical failure for patients with intermediate and high-risk prostate cancer treated by definitive radiotherapy.
First Author: Hye Jin Kang